S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Investors Urged to Join Securities Fraud Class Action Against Anavex

Investors who purchased Anavex Life Sciences Corp. stock between November 26, 2025, and August 28, 2026, face a November 30 deadline to seek lead plaintiff status in a pending class action lawsuit filed by Schall, Brown & Schwartz LLP regarding alleged federal securities violations.

Investors Urged to Join Securities Fraud Class Action Against Anavex
Photo: Bio & News

The litigation targets Anavex for alleged violations of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a). The complaint asserts that the company issued false and misleading statements to the market while failing to maintain sufficient internal controls. Central to the allegations are claims that the firm downplayed regulatory challenges stemming from the conduct of former CEO Christopher Missling. Investors reportedly sustained financial damages when these issues surfaced.

Schall, Brown & Schwartz LLP is currently soliciting shareholders who suffered losses during the specified period to participate in the case. While the class has not yet received legal certification, the firm is offering consultations with partners Brian Schall and David Schwartz to discuss potential recovery options. Participation in the lawsuit does not require an appointment as lead plaintiff, and shareholders who choose to remain absent class members will not be represented by the firm unless they formally join the action.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!